Induction failure in granulomatosis with polyangiitis : a nationwide case-control study of risk factors and outcomes
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVE: To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy.
METHODS: We conducted a nationwide retrospective case-control study of GPA with induction failure between 2006 and 2021. Each patient with induction failure was randomly paired to three controls matched for age, sex and induction treatment.
RESULTS: We included 51 patients with GPA and induction failure (29 men and 22 women). At induction therapy, median age was 49 years. Twenty-seven patients received intravenous cyclophosphamide (ivCYC) and 24 rituximab (RTX) as induction therapy. Patients with ivCYC induction failure more frequently had PR3-ANCA (93% vs 70%, P = 0.02), relapsing disease (41% vs 7%, P < 0.001) and orbital mass (15% vs 0%, P < 0.01) compared with controls. Patients with disease progression despite RTX induction therapy more frequently had renal involvement (67% vs 25%, P = 0.02) with renal failure (serum creatinine >100 µmol/l in 42% vs 8%, P = 0.02) compared with controls. After salvage therapy, remission was achieved at 6 months in 35 (69%) patients. The most frequent salvage therapy was switching from ivCYC to RTX (or vice versa), showing an efficacy in 21/29 (72%). Remission was achieved in nine (50%) patients with inappropriate response to ivCYC, while in patients with progression after RTX induction, remission was achieved in four (100%) who received ivCYC (with or without immunomodulatory therapy), but only in three (50%) after adding immunomodulatory therapy alone.
CONCLUSION: In patients with induction failure, characteristics of GPA, salvage therapies and their efficacy vary according to induction therapy and failure modality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 62(2023), 11 vom: 02. Nov., Seite 3662-3671 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sorin, Boris [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 14.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/kead098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353535656 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353535656 | ||
| 003 | DE-627 | ||
| 005 | 20231226060227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353535656 | ||
| 035 | |a (NLM)36847447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sorin, Boris |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Induction failure in granulomatosis with polyangiitis |b a nationwide case-control study of risk factors and outcomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 14.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy | ||
| 520 | |a METHODS: We conducted a nationwide retrospective case-control study of GPA with induction failure between 2006 and 2021. Each patient with induction failure was randomly paired to three controls matched for age, sex and induction treatment | ||
| 520 | |a RESULTS: We included 51 patients with GPA and induction failure (29 men and 22 women). At induction therapy, median age was 49 years. Twenty-seven patients received intravenous cyclophosphamide (ivCYC) and 24 rituximab (RTX) as induction therapy. Patients with ivCYC induction failure more frequently had PR3-ANCA (93% vs 70%, P = 0.02), relapsing disease (41% vs 7%, P < 0.001) and orbital mass (15% vs 0%, P < 0.01) compared with controls. Patients with disease progression despite RTX induction therapy more frequently had renal involvement (67% vs 25%, P = 0.02) with renal failure (serum creatinine >100 µmol/l in 42% vs 8%, P = 0.02) compared with controls. After salvage therapy, remission was achieved at 6 months in 35 (69%) patients. The most frequent salvage therapy was switching from ivCYC to RTX (or vice versa), showing an efficacy in 21/29 (72%). Remission was achieved in nine (50%) patients with inappropriate response to ivCYC, while in patients with progression after RTX induction, remission was achieved in four (100%) who received ivCYC (with or without immunomodulatory therapy), but only in three (50%) after adding immunomodulatory therapy alone | ||
| 520 | |a CONCLUSION: In patients with induction failure, characteristics of GPA, salvage therapies and their efficacy vary according to induction therapy and failure modality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ANCA-associated vasculitides | |
| 650 | 4 | |a CYC | |
| 650 | 4 | |a granulomatosis with polyangiitis | |
| 650 | 4 | |a induction failure | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Iudici, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Guerry, Mary-Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Samson, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Bielefeld, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Maillet, Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Nouvier, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Lavigne, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Régent, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Durel, Cécile-Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Fabre, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Raimbourg, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Lanteri, Aurélia |e verfasserin |4 aut | |
| 700 | 1 | |a Pugnet, Grégory |e verfasserin |4 aut | |
| 700 | 1 | |a Rivière, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Pineton de Chambrun, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Cacoub, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guenno, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Jourdain, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Mekinian, Arsène |e verfasserin |4 aut | |
| 700 | 1 | |a Paule, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Dion, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Legendre, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Guillevin, Loïc |e verfasserin |4 aut | |
| 700 | 1 | |a Puéchal, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 62(2023), 11 vom: 02. Nov., Seite 3662-3671 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:11 |g day:02 |g month:11 |g pages:3662-3671 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 11 |b 02 |c 11 |h 3662-3671 | ||